| Name | Title | Contact Details |
|---|---|---|
Karen Sheehy |
General Counsel | Profile |
Michael Halstead |
General Counsel | Profile |
Silicon Therapeutics is an integrated physics driven drug discovery company focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our platform closely represents the real dynamical nature of targets using accurate all-atom simulations, enabling us to design and optimize compounds for targets that were previously considered "undruggable." Our science, our team, and our mission are focused on applying advanced computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China
Stanbio Laboratory is committed to manufacture and market a complete line of high quality clinical diagnostic products with an unmatched level of service and support. We provide an excellent working environment in which we develop and refine our
Frontida BioPharm is a Minority-Owned Contract Development & Manufacturing Organization. We work collaboratively with our clients to bring new and improved products to the pharmaceutical market. By leveraging our team`s vast knowledge and experience we are able to improve the success of our client`s business and product development efforts. Frontida was launched by founding management team members of Frontage Laboratories. Having 15 years of success in the business Frontage remains a thriving CRO that has become a full service R&D organization located in PA, NJ, and China. With strong record of FDA compliance and quality service to global pharmaceutical and biotechnology companies, the Frontage team easily founded Frontida. While Frontage and Frontida remain affiliates, they are separate business entities.
Jamol Laboratories is a Emerson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.